AXIM BIOTECHNOLOGIES INC - AXIM STOCK NEWS

AXIM Biotechnologies, Inc. has published its research in the Journal of Clinical Virology, detailing a novel rapid test to measure neutralizing antibodies against SARS-CoV-2. This test requires only a drop of blood and is highly effective, showcasing over 90% sensitivity and 100% specificity. It can be used at point-of-care settings and does not cross-react with antibodies from other respiratory infections. The test assists in monitoring immunity levels, which could inform decisions about booster vaccinations.

AXIM Biotechnologies has appointed Dr. Michael E. Stern to its Medical Advisory Board. Dr. Stern, with over 30 years of expertise in Dry Eye Disease and Ocular Surface Disease, is the Chief Science Officer at immunEyze and has previously worked at Allergan. The company aims to leverage his experience as it prepares to commercialize its FDA-approved diagnostic tests for Dry Eye Disease. AXIM targets a growing global market, with over 300 million affected individuals, highlighting the need for improved diagnostic tools.

AXIM Biotechnologies appointed Dr. Kelly K. Nichols, an expert in ocular surface disease and Dean of the School of Optometry at the University of Alabama at Birmingham, to its Medical Advisory Board. This strategic enhancement aims to augment the board's value and facilitate effective communication regarding dry eye disease (DED) diagnostics. Dr. Nichols' extensive experience will aid in marketing communications for upcoming DED diagnostic tests, set for commercial launch in early 2022. With over 26 million affected in the US, addressing DED's underdiagnosis is becoming increasingly critical.

AXIM Biotechnologies has developed a second-generation Rapid Neutralizing Antibody Test for COVID-19, aimed at improving detection of protective antibodies. This new test can differentiate between non-neutralizing and neutralizing antibodies, providing users with valuable information on their vaccine response in just 10 minutes. The company’s first test is currently under FDA review. AXIM aims to enhance diagnostics for COVID-19 and other diseases through its innovative solutions, which include rapid tests for oncological and ophthalmological conditions.

AXIM Biotechnologies has announced the appointment of Dr. Henry D. Perry to its Medical Advisory Board, marking him as the third member. Dr. Perry, a leading US cornea and refractive surgeon, brings decades of clinical and research expertise. He is recognized for his contributions in ophthalmology and has received numerous accolades, including the Life Achievement Award from the American Academy of Ophthalmology. CEO John W. Huemoeller II expressed optimism regarding Dr. Perry's role in enhancing AXIM's capabilities in diagnosing dry eye disease, which affects millions globally.

AXIM Biotechnologies has appointed Dr. Laura M. Periman to its Medical Advisory Board, joining Chairman Dr. Joseph Tauber. Dr. Periman brings 30 years of medical experience, specializing in ocular surface disease and dry eye disease (DED). She aims to enhance AXIM’s strategy for commercializing ophthalmic diagnostic tests, particularly given the growing global prevalence of DED, affecting over 300 million people. AXIM, founded in 2014, is focused on innovative diagnostics for COVID-19, DED, and cancer.

AXIM Biotechnologies has appointed Dr. Joseph Tauber as Chief Medical Officer and Chairman of its Medical Advisory Board. Dr. Tauber, a leading expert in dry eye disease with over 30 years of clinical experience, has participated in over 140 research studies and played a key role in the development of FDA-approved treatments for dry eye. The company aims to enhance DED diagnostics under Dr. Tauber’s guidance, addressing the needs of over 26 million Americans suffering from this condition. The appointment is expected to strengthen AXIM's position in the growing dry eye disease market.

AXIM Biotechnologies has appointed Jeffrey A. Busby as Senior Vice President – Business Development. Busby has over 30 years of experience in ophthalmic medical device sales.

He will lead the launch of recently acquired diagnostic technologies for dry eye disease (DED), including two FDA cleared tests approved for reimbursement. The launch is set for early 2022, with expectations to drive revenue. AXIM aims to enhance its position as a premier medical diagnostics company, targeting the growing DED market, which affects approximately 20 million people in the US.

SAN DIEGO, Aug. 30, 2021 – AXIM Biotechnologies (OTCQB: AXIM) announced that its manufacturing partner, Empowered Diagnostics, has filed an amended emergency use authorization (EUA) with the FDA for its COVID-19 neutralizing antibody rapid test, ImmunoPass™. The amendment includes updated clinical trials and studies to validate the test's accuracy. CEO John W. Huemoeller II emphasized the ease of use and fast results of ImmunoPass, aligning with the ongoing demand for COVID-19 antibody testing.